Research presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting, held April 27-28, 2020, found that the combination of atezolizumab (Tecentriq) plus cobimetinib (Cotellic) improved cancer control in some patients with biliary tract cancer.1
“We wanted to see if combining the 2 drugs resulted in improved anticancer activity in biliary tract cancer,” Mark Yarchoan, MD, assistant professor of oncology at Johns Hopkins Kimmel Cancer, said in a press release.2 To find out if the combination was effective, Yarchoan and his colleagues decided to compare the benefit of atezolizumab alone vs atezolizumab plus cobimetinib in a randomized study.
Currently, the standard therapy for patients who have advanced disease is a combination of gemcitabine (Gemzar) and cisplatin, however the survival of patients receiving standard treatment is less than 1…
